The underlying mechanisms of overcoming EGFR-TKIs resistance by casein kinase 2 inhibitor

VernacularTitle:蛋白激酶2抑制剂克服表皮生长因子受体-酪氨酸激酶抑制剂耐药的有效机制
Author: Yu ZHOU ¹ ; Sheng ZHANG ; Ke LI ; Xiaorong DONG ; Li LIU ; Gang WU ; Rui MENG
Author Information

1. 华中科技大学同济医学院附属协和医院肿瘤中心
Keywords: Subject words] Lung neoplasms; Epidermal growth factor receptor-tyrosine kinase inhibitors; Protein kinase 2; Drug resistance,neoplasm
From: Chinese Journal of Oncology 2016;38(5):321-324
CountryChina
Language:Chinese
Abstract: Nowadays, EGFR?TKIs are important treatment strategy in lung cancer, but the resistance to EGFR?TKIs remains an unsolved issue preventing the patients from further benefits. Recent studies have shown that casein kinase ( CK2) plays an important role in carcinogenesis and development of cancer. CK2 inhibitor has also demonstrated anti?tumor effects. Here we reviewed the mechanism of EGFR?TKIs and the potential reasons of resistance. Interestingly, there is a crosstalk between CK2 and EGFR downstream signaling pathways, therefore, it may be possible that CK2 inhibitor can overcome the EGFR?TKIs resistance.